G1 Therapeutics, Inc. (GTHX)

Market Cap	136.38M
Revenue (ttm)	51.30M
Net Income (ttm)	-147.56M
Shares Out	51.66M
EPS (ttm)	-3.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	690,723
Open	2.76
Previous Close	2.79
Day's Range	2.61 - 2.83
52-Week Range	2.55 - 17.49
Beta	1.82
Analysts	Buy
Price Target	14.11 (+434.47%)
Earnings Date	May 3, 2023

About GTHX

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 17, 2017
• Employees: 148
• Stock Exchange: NASDAQ
• Ticker Symbol: GTHX

Financial Performance

In 2022, GTHX's revenue was $51.30 million, an increase of 62.98% compared to the previous year's $31.48 million. Losses were -$147.56 million, -0.53% less than in 2021.

Analyst Forecast

According to 14 analysts, the average rating for GTHX stock is "Buy." The 12-month stock price forecast is $14.11, which is an increase of 434.47% from the latest price.

Price Target

$14.11

(434.47% upside)

Analyst Consensus: Buy